Baidu
map

中国医药报:“保健”市场乱象严重危害民生,须“社会共治”

2019-01-23 佚名 中国医药报

“保健”市场乱象严重危害民生,严重影响经济高质量发展,严重破坏社会和谐稳定。1月8日,国家市场监管总局联合多部门在京召开整治“保健”市场乱象百日行动电视电话会议,部署开展“百日行动”。据悉,本次“百日行动”从2019年1月8日开始,为期100天。市场监管总局、工业和信息化部、公安部、民政部、住房城乡建设部、农业农村部、商务部、文化和旅游部、卫生健康委、广电总局、中医药局、药监局、网信办等13个部门

“保健”市场乱象严重危害民生,严重影响经济高质量发展,严重破坏社会和谐稳定。1月8日,国家市场监管总局联合多部门在京召开整治“保健”市场乱象百日行动电视电话会议,部署开展“百日行动”。据悉,本次“百日行动”从2019年1月8日开始,为期100天。市场监管总局、工业和信息化部、公安部、民政部、住房城乡建设部、农业农村部、商务部、文化和旅游部、卫生健康委、广电总局、中医药局、药监局、网信办等13个部门将在全国范围内加大对“保健”市场重点行业、重点领域、重点行为的事中事后监管力度,依法严厉打击虚假宣传、虚假广告、制售假冒伪劣产品等扰乱市场秩序、欺诈消费者等各类违法行为。

近年来,随着公众日益增长的健康消费需求,“保健”市场犹如雨后春笋般快速发展,且在我国已形成一个巨大的产业,预计到2020年,中国将成为全球第二大健康营养品消费市场。

然而,在产业快速发展的同时,制假售假、假冒文号、非法添加、虚假宣传、夸大功效等问题屡见不鲜,屡禁不止,“保健”市场乱象广受社会诟病,成为影响整个行业持续健康发展的“毒瘤”,也严重危害了广大消费者的合法权益和身心健康。最近,引爆媒体圈的“权健事件”即是一个缩影。

为促进行业规范运行、良性发展,维护公众健康权益,近年来,国家相关部门一直在不断发力,《食品安全法》《广告法》的修订实施,《保健食品注册与备案管理办法》的发布,我国对保健食品的管理愈加详尽科学,惩戒措施也更为严厉。《食品安全法》规定,任何食品均应符合安全标准,不得使用来源不明的食材或不符合标准的添加剂。根据《广告法》,保健食品广告不得含有表示功效、安全性的断言或者保证;涉及疾病预防、治疗功能;声称或者暗示广告商品为保障健康所必需;与药品、其他保健食品进行比较等内容。违规者不仅应受到《食品安全法》规定的十五万元以下罚款的处罚,还可能受到《广告法》规定的二十万元以上一百万元以下的罚款,更可能受到刑法的惩戒。

尽管如此,依然有部分商家我行我素,置法律法规于不顾。净化“保健”市场,保护消费者合法权益,迫在眉睫。目前,按照天津市委、市政府的统一部署,天津市市场监管委会同10部门已率先开展了为期3个月的集中打击清理整顿“保健”市场乱象专项整治行动,也希望各地以整治“保健”市场乱象百日行动为契机,对“保健”市场来一次严厉的清理整顿,还“保健”市场一片蓝天,给消费者营造一个健康的“保健”环境。

当然,“保健”市场乱象治理是一个大问题,不能单靠政府部门,要有社会治理理念和意识,必须走社会共治的道路。

首先,必须高悬法律之剑,让法律法规执行落实到位,让良法得到充分善治。对违法法规、虚假宣传的营销机构、个人,必须依法立案查处,顶格处罚,提高违法违规成本。

其次,加强治理,对相关机构进行征信管理,建立社会信用档案。把在“保健”市场领域有重大违规营销行为的举办者、品种纳入监管“黑名单”,增加巡查频次和密度,畅通群众举报渠道;同时,加强与公安机关的联系沟通,通过大数据方法,建立违法违规营销精准识别和联合惩戒机制;改变单一管理模式,严防管理漏洞。严格执行《保健食品注册与备案管理办法》要求的“建立注册与备案相结合的管理模式”的规定;及时曝光违法违规保健食品及其营销活动,遏制保健食品营销乱象。

第三,尽快出台明确的行业规范和标准。既要提高行业准入标准,又要有明确的“退出”机制和严格的处罚制度。还要做好相关的科普教育工作,提高消费者识假、辨假、拒假能力和科学保健、科学治疗意识,从消费终端倒逼假冒伪劣产品退出市场。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2079772, encodeId=25a720e977205, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Mon Aug 19 11:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019729, encodeId=f5dc2019e2977, content=<a href='/topic/show?id=c88ce3951bf' target=_blank style='color:#2F92EE;'>#社会共治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73951, encryptionId=c88ce3951bf, topicName=社会共治)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Nov 02 22:21:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755284, encodeId=e76b1e552841a, content=<a href='/topic/show?id=14e123562d0' target=_blank style='color:#2F92EE;'>#乱象#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23562, encryptionId=14e123562d0, topicName=乱象)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=842136851119, createdName=zhangjingnwpu, createdTime=Sat Nov 30 03:21:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409786, encodeId=191f1409e8645, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616930, encodeId=545816169302d, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2079772, encodeId=25a720e977205, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Mon Aug 19 11:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019729, encodeId=f5dc2019e2977, content=<a href='/topic/show?id=c88ce3951bf' target=_blank style='color:#2F92EE;'>#社会共治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73951, encryptionId=c88ce3951bf, topicName=社会共治)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Nov 02 22:21:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755284, encodeId=e76b1e552841a, content=<a href='/topic/show?id=14e123562d0' target=_blank style='color:#2F92EE;'>#乱象#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23562, encryptionId=14e123562d0, topicName=乱象)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=842136851119, createdName=zhangjingnwpu, createdTime=Sat Nov 30 03:21:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409786, encodeId=191f1409e8645, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616930, encodeId=545816169302d, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2079772, encodeId=25a720e977205, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Mon Aug 19 11:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019729, encodeId=f5dc2019e2977, content=<a href='/topic/show?id=c88ce3951bf' target=_blank style='color:#2F92EE;'>#社会共治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73951, encryptionId=c88ce3951bf, topicName=社会共治)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Nov 02 22:21:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755284, encodeId=e76b1e552841a, content=<a href='/topic/show?id=14e123562d0' target=_blank style='color:#2F92EE;'>#乱象#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23562, encryptionId=14e123562d0, topicName=乱象)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=842136851119, createdName=zhangjingnwpu, createdTime=Sat Nov 30 03:21:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409786, encodeId=191f1409e8645, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616930, encodeId=545816169302d, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2079772, encodeId=25a720e977205, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Mon Aug 19 11:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019729, encodeId=f5dc2019e2977, content=<a href='/topic/show?id=c88ce3951bf' target=_blank style='color:#2F92EE;'>#社会共治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73951, encryptionId=c88ce3951bf, topicName=社会共治)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Nov 02 22:21:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755284, encodeId=e76b1e552841a, content=<a href='/topic/show?id=14e123562d0' target=_blank style='color:#2F92EE;'>#乱象#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23562, encryptionId=14e123562d0, topicName=乱象)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=842136851119, createdName=zhangjingnwpu, createdTime=Sat Nov 30 03:21:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409786, encodeId=191f1409e8645, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616930, encodeId=545816169302d, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]
    2019-01-25 cathymary
  5. [GetPortalCommentsPageByObjectIdResponse(id=2079772, encodeId=25a720e977205, content=<a href='/topic/show?id=0e9421e61cb' target=_blank style='color:#2F92EE;'>#中国医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21761, encryptionId=0e9421e61cb, topicName=中国医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=zhangpaul93, createdTime=Mon Aug 19 11:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2019729, encodeId=f5dc2019e2977, content=<a href='/topic/show?id=c88ce3951bf' target=_blank style='color:#2F92EE;'>#社会共治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73951, encryptionId=c88ce3951bf, topicName=社会共治)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Nov 02 22:21:00 CST 2019, time=2019-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755284, encodeId=e76b1e552841a, content=<a href='/topic/show?id=14e123562d0' target=_blank style='color:#2F92EE;'>#乱象#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23562, encryptionId=14e123562d0, topicName=乱象)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=842136851119, createdName=zhangjingnwpu, createdTime=Sat Nov 30 03:21:00 CST 2019, time=2019-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409786, encodeId=191f1409e8645, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616930, encodeId=545816169302d, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Fri Jan 25 02:21:00 CST 2019, time=2019-01-25, status=1, ipAttribution=)]

相关资讯

2018“中国高等学校十大科技进展”出炉

教育部“点名表扬”2项生物医药科技成果……

2018ASH进展盘点:邱录贵教授:多发性骨髓瘤基础与临床进展齐飞,中国贡献举足轻重

2018年度美国血液学年会(ASH)已于12月1-4日在美国圣地亚哥顺利举行。此次ASH会议上,多发性骨髓瘤(MM)研究无论在临床试验还是基础研究方面都取得了令人瞩目的成就。

SCI 正式收录STTT《Signal Transduction and Targeted Therapy》

近日,由四川大学华西医院/生物治疗国家重点实验室与Nature出版集团合办的英文学术期刊《Signal Transduction and Targeted Therapy(STTT)》被SCI数据库正式收录,第一次的影响因子将在今年六月发布。

重磅|实现每个中国人的心血管健康

2018年12月28日,恰逢中国心血管健康联盟3岁和中华医学会心血管病学分会40岁的历史盛事,在我国心血管医学历史的文化标志和根据地——中国心血管医学博物馆里,刘力生教授、刘兰琦教授、蒋文平教授、叶大训教授、郭静萱教授等老一辈心血管专家们汇聚一堂,为这“一老一少”隆重庆生。中国心血管健康联盟主席葛均波院士代表每一个联盟人许下了“实现每个中国人的心血管健康”的生日愿望,刘力生教授更是欣然地写下:“希

Asian Pac J Allergy Immunol:中国过敏性鼻炎与哮喘并发流行度分析

过敏性鼻炎(AR)和哮喘是呼吸道最常见的炎症疾病。哮喘与AR的关系已经有很广泛的研究。"One airway, one disease"的概念已经被逐渐的接受。然而,在中国还没有对AR携带哮喘和哮喘携带AR的流行度进行系统的回顾和元分析。最近,有研究人员对所有已经发表达的研究结果进行了元分析,并呈现中国AR携带哮喘和哮喘携带AR并发比例的确定信息。研究人员对各大数据Pubmed/Medline、S

数说中国医疗卫生40年 这些事情你都知道吗

40年,岁月如歌。中国的跨越发展,造就了世界上最美的风景。从1978年到2018年,从开启新时期到跨入新世纪,从站上新起点到进入新时代,40年风雨同舟,披荆斩棘,砥砺奋进。回首我国在各个领域翻天覆地的变化,医疗卫生领域发生的巨变,可以称得上独树一帜。从早期群众看病的老三样“听诊器、血压计、体温表”,到如今的“B超、CT、核磁共振”;从背着药箱穿街走巷的“赤脚医生”到互联网医院专家远程问诊;从条

Baidu
map
Baidu
map
Baidu
map